Wolf Group Capital Advisors Purchases New Holdings in Boston Scientific Corporation (NYSE:BSX)

Wolf Group Capital Advisors acquired a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The fund acquired 21,255 shares of the medical equipment provider's stock, valued at approximately $2,144,000.

A number of other institutional investors have also recently added to or reduced their stakes in BSX. Colonial Trust Co SC lifted its holdings in Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after buying an additional 260 shares in the last quarter. Investment Management Corp VA ADV acquired a new position in Boston Scientific in the 4th quarter worth $25,000. Sunbeam Capital Management LLC acquired a new position in Boston Scientific in the 4th quarter worth $26,000. Ameriflex Group Inc. acquired a new position in Boston Scientific in the 4th quarter worth $31,000. Finally, Fairway Wealth LLC acquired a new position in Boston Scientific in the 4th quarter worth $36,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

NYSE BSX traded down $0.37 on Thursday, hitting $101.36. The stock had a trading volume of 5,188,625 shares, compared to its average volume of 6,586,240. Boston Scientific Corporation has a one year low of $71.88 and a one year high of $107.17. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47. The stock has a market cap of $149.96 billion, a price-to-earnings ratio of 73.99, a P/E/G ratio of 2.62 and a beta of 0.68. The company's 50-day moving average is $101.44 and its two-hundred day moving average is $98.91.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The firm had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter in the prior year, the firm earned $0.56 EPS. Boston Scientific's quarterly revenue was up 20.9% on a year-over-year basis. On average, analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Leerink Partners assumed coverage on shares of Boston Scientific in a research report on Monday. They issued an "outperform" rating and a $118.00 target price for the company. Royal Bank Of Canada boosted their target price on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Barclays boosted their target price on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Finally, Citigroup reissued a "buy" rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Twenty-two research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average target price of $116.09.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total value of $1,767,066.84. Following the completion of the sale, the executive vice president now directly owns 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This represents a 43.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the sale, the chief executive officer now directly owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. This represents a 9.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 411,970 shares of company stock valued at $42,406,693. Company insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.